Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trialsAlexander Drilon, Robert C. Doebele, Christos S. Karapetis et al.|The Lancet Oncology|2019Cited by 537
The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancersG. Saturno, Caroline J. Springer, Filipa M. Lopes et al.|Annals of Oncology|2020Cited by 21
A first-in-human phase 1 trial of nx-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced solid tumor malignancies.Adam Sharp, Hendrik‐Tobias Arkenau, Anja Williams et al.|Journal of Clinical Oncology|2022Cited by 12
A First-in-Human Phase 1 Trial of NX-1607, a First-in-Class Oral CBL-B Inhibitor, in Patients with Advanced Malignancies Including DLBCLGraham P. Collins, Dima El‐Sharkawi, William Townsend et al.|Blood|2023Cited by 9
PB2099: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-1607, A FIRST-IN-CLASS ORAL CBL-B INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES INCLUDING RICHTER TRANSFORMATION DLBCLAdam Sharp, Hendrick-Tobias Arkenau, A. Williams et al.|HemaSphere|2022Cited by 5